Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P.
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
Lancet. 2018 Jan 20;391(10117):230-240.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH.
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
N Engl J Med. 2001 May 10;344(19):1434-41.

Leder BZ, Mitlak B, Hu MY, Hattersley G, Bockman RS.
Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
J Clin Endocrinol Metab. 2020 Mar 1;105(3):938-43.

Brown JP, Engelke K, Keaveny TM, Chines A, Chapurlat R, Foldes AJ, Nogues X, Civitelli R, De Villiers T, Massari F, Zerbini CAF, Wang Z, Oates MK, Recknor C, Libanati C.
Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial.
J Bone Miner Res. 2021 Nov;36(11):2139-2152.

Tsai JN, Lee H, David NL, Eastell R, Leder BZ.
Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial.
Lancet Diabetes Endocrinol. 2019 Oct;7(10):767-775.

Reid IR, Billington EO.
Drug therapy for osteoporosis in older adults.
Lancet. 2022 Mar 12;399(10329):1080-1092.

McClung MR, Clark AL.
Osteoanabolic therapy for osteoporosis in women.
Climacteric. 2022 Feb;25(1):60-66.

Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, Harvey N, Kanis J, Leyland S, Low R, McCloskey E, Moss K, Parker J, Paskins Z, Poole K, Reid DM, Stone M, Thomson J, Vine N, Compston
UK clinical guideline for the prevention and treatment of osteoporosis.
J. Arch Osteoporos. 2022 Apr 5;17(1):58.

Bandeira L, Lewiecki EM.
Anabolic therapy for osteoporosis: update on efficacy and safety.
Arch Endocrinol Metab. 2022 Nov 11;66(5):707-716.

Rozenberg S, Vandromme J, Revercez P, Valcarenghi M, Joris A.
Menopause Hormone Therapy in the Management of Postmenopausal Osteoporosis.
Cancer J. 2022 May-Jun 01;28(3):204-207.

M. S. LeBoff, S. L. Greenspan, K. L. Insogna, E. M. Lewiecki, K. G. Saag, A. J. Singer, E. S. Siris
The clinician's guide to prevention and treatment of osteoporosis
Osteoporos Int. 2022; 33(10): 2049–2102.

Agustín Aibar-Almazán, Ana Voltes-Martínez, Yolanda Castellote-Caballero, Diego Fernando Afanador-Restrepo, María del Carmen Carcelén-Fraile, Elena López-Ruiz
Current Status of the Diagnosis and Management of Osteoporosis
Int J Mol Sci. 2022 Aug; 23(16): 9465.

Michaël R. Laurent, Stefan Goemaere, Charlotte Verroken, Pierre Bergmann, Jean-Jacques Body, Olivier Bruyčre, Etienne Cavalier, Serge Rozenberg, Bruno Lapauw, Evelien Gielen
Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club
Front Endocrinol (Lausanne) 2022; 13: 908727.

Xueli Yang, Tian Chang, Qian Yuan, Wei Wei, Pingping Wang, Xiaojian Song, Huijuan Yuan
Changes in the composition of gut and vaginal microbiota in patients with postmenopausal osteoporosis
Front Immunol. 2022; 13: 930244.

Aayushi Bhatnagar, Aditya L Kekatpure
Postmenopausal Osteoporosis: A Literature Review
Cureus. 2022 Sep; 14(9): e29367.

Elizabeth M. Curtis, Jean-Yves Reginster, Nasser Al-Daghri, Emmanuel Biver, Maria Luisa Brandi, Etienne Cavalier, Peyman Hadji, Philippe Halbout, Nicholas C. Harvey, Mickaël Hiligsmann, M. Kassim Javaid, John A. Kanis, Jean-Marc Kaufman, Olivier Lamy, Radmila Matijevic, Adolfo Diez Perez, Régis Pierre Radermecker, Mário Miguel Rosa, Thierry Thomas, Friederike Thomasius, Mila Vlaskovska, René Rizzoli, Cyrus Cooper
Management of patients at very high risk of osteoporotic fractures through sequential treatments
Aging Clin Exp Res. 2022; 34(4): 695–714.

Manju Chandran, Peter R. Ebeling, Paul J Mitchell, Tuan V. Nguyen, the Executive Committee of the Asia Pacific Consortium on Osteoporosis (APCO)
Harmonization of Osteoporosis Guidelines: Paving the Way for Disrupting the Status Quo in Osteoporosis Management in the Asia Pacific
J Bone Miner Res. 2022 Apr; 37(4): 608–615.

P. Chotiyarnwong, E. V. McCloskey, N. C. Harvey, M. Lorentzon, D. Prieto-Alhambra, B. Abrahamsen, J. D. Adachi, F. Borgström, O. Bruyere, J. J. Carey, P. Clark, C. Cooper, E. M. Curtis, E. Dennison, M. Diaz-Curiel, H. P. Dimai, D. Grigorie, M. Hiligsmann, P. Khashayar, E. M. Lewiecki, P. Lips, R. S. Lorenc, S. Ortolani, A. Papaioannou, S. Silverman, M. Sosa, P. Szulc, K. A. Ward, N. Yoshimura, J. A. Kanis
Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group
Arch Osteoporos. 2022; 17(1): 87.